taVNS

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique that delivers electrical stimulation to the auricular branch of the vagus nerve through the skin of the external ear. Most protocols target areas such as the cymba concha or the tragus, using surface electrodes or clip-on devices. By stimulating afferent fibers of the vagus nerve, taVNS aims to influence neural circuits involved in autonomic regulation and brain networks, while avoiding the surgical risks of implanted vagus nerve stimulation.

The presumed mechanism involves activation of afferent pathways to the brainstem, including the nucleus tractus solitarius and locus coeruleus, with downstream modulation of limbic, thalamic, and cortical regions. This can modulate autonomic balance and may engage the cholinergic anti-inflammatory pathway, potentially reducing systemic inflammation in some conditions.

Investigations of taVNS have explored pain, mood disorders such as depression and anxiety, epilepsy, tinnitus, migraine, and inflammatory or autoimmune conditions. Evidence is preliminary and results across studies are mixed, with heterogeneity in stimulation parameters, electrode placement, and outcome measures. Commonly used protocols deliver low-frequency pulses (often around 1–30 Hz) with amplitudes adjusted to a comfortable sensory threshold, for sessions ranging from several minutes to around 30 minutes, several times per week.

Safety and tolerability are generally favorable. Reported adverse effects include mild skin irritation, tingling, or dizziness in some individuals. Contraindications or precautions include skin lesions at the stimulation site or the presence of certain implanted medical devices; users should follow device guidance and consult clinicians for medical considerations.

Overall, taVNS is an area of active research with potential therapeutic applications, but robust evidence to support routine clinical use remains limited and regulatory status varies by jurisdiction.